According to guidelines for the diagnosis and treatment of heart failure set by the Chinese government in 2018, angiotensin-converting enzyme inhibitors (ACEIs), β-receptor blockers, and aldosterone receptor antagonists are recommended as “the golden triangle treatment” for patients suffering from CHF with reduced ejection fraction (Heart Failure Group of Chinese Society of Cardiology and Editorial Board of Chinese Journal of Cardiology, 2018). The gene discussed is NR3C2; the disease is heart failure.